Rosetta Genomics Receives Accreditation from College of American Pathologists for its Laboratory in California

Reflects high-quality standards of the laboratory

PRINCETON, N.J. & REHOVOT, Israel--(BUSINESS WIRE)-- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Accreditation Committee of the College of American Pathologists (CAP) has approved re-accreditation to Rosetta Genomics’, Lake Forest, CA laboratory based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.

The facility’s laboratory director, Alfred Lui, MD, was notified of this national recognition and congratulated for the excellence of the services being provided. Rosetta Genomics’ Lake Forest laboratory, along with its laboratory in Philadelphia, PA, are among the more than 7,700 CAP-accredited facilities worldwide.

“Ongoing accreditation from CAP indicates compliance with the most demanding good laboratory procedures and indicates that the laboratory meets or exceeds regulatory requirements,” stated Dr. Lui. “Receiving CAP Accreditation reaffirms our commitment to providing the highest standard of cutting edge diagnostic techniques.”

Commenting on the laboratory’s continued accreditation, Kenneth A. Berlin, Rosetta Genomics’ President and Chief Executive Officer, said, “The quality of our laboratory and testing services has always been a core competency for Rosetta Genomics. We remain committed to the development and performance of high-value as well as high-quality molecular diagnostic testing services that advance personalized medicine.”

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the government’s own inspection program.

During the CAP accreditation process, designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

About the College of American Pathologists

As the leading organization with more than 18,000 board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP’s Laboratory Improvement Programs, initiated 65 years ago, currently have customers in more than 100 countries, accrediting 7,700 laboratories and providing proficiency testing to 20,000 laboratories worldwide. Find more information about the CAP at cap.org. Follow CAP on Twitter: @pathologists.

About Rosetta Genomics

Rosetta develops and commercializes a broad range of microRNA-based and other high-value molecular diagnostics. Rosetta’s integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Through the acquisition of PersonalizeDx, the Company also offers core FISH, IHC and PCR-based testing capabilities and partnerships in oncology and urology that provide additional content and platforms that complement the Rosetta offerings. Rosetta’s cancer testing services are commercially available through the Philadelphia, PA- and Lake Forest, CA-based CAP-accredited, CLIA-certified labs, respectively. For more information visit www.rosettagenomics.com.

Forward-Looking Statement Disclaimer

Various statements in this release concerning Rosetta’s future expectations, plans and prospects including, but not limited to statements relating to Rosetta Genomics advancing personalized medicine, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2014 as filed with the SEC. In addition, any forward-looking statements represent Rosetta’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150806005207/en/

Rosetta Genomics
Ken Berlin, 609-419-9003
President & CEO
[email protected]
or
Investors:
LHA
Anne Marie Fields, 212-838-3777
[email protected]
or
Bruce Voss, 310-691-7100
[email protected]

Source: Rosetta Genomics Ltd.

You May Also Be Interested In

• My Size (MYSZ) Announces 1:8 Reverse Share Split
• Cassava Sciences (SAVA) Sets May 6th as Final Day to Exercise Warrants
• NextPlat Corp (NXPL) Announces Proposed Merger with Progressive Care (RXMD)